In the previously mentioned meta-analysis by Li et al
Patients and healthcare providers should collaborate, modifying approaches as symptoms evolve
PT-141 Research# PT-141 completed the full drug development pathway: RECONNECT trials : Two Phase 3 pivotal trials in premenopausal women with HSDD demonstrated statistically significant improvements in sexual desire scores compared to placebo, with a meaningful increase in satisfying sexual events FDA approval : Approved June 21, 2019, as Vyleesi for HSDD in premenopausal women Male sexual dysfunction : Earlier trials explored PT-141 for male erectile dysfunction, though this indication was not pursued to approval Dose limitations : FDA label restricts use to no more than 8 doses per month and recommends against use in patients with uncontrolled hypertension or cardiovascular disease Post-marketing : Ongoing pharmacovigilance with established adverse event reporting The regulatory gap between MT-2 and PT-141 is the fundamental differentiator: PT-141 has undergone the rigorous efficacy and safety evaluation required for FDA approval, while MT-2 has not
Tirzepatide is an advanced medication originally developed for people living with obesity or type 2 diabetes
These beneficial effects of GLP-1RA on MACE are independent of many variable including the presence of established CV disease at baseline, the structural basis of GLP-1RA (exendin-4 based agonists vs
From top to bottom, the new ED is built to save lives
